Key result
Therapies approved for pulmonary arterial hypertension may provide benefits in patients with single-ventricle physiology experiencing progressive failure of the Fontan circulation.
Therapies approved for pulmonary arterial hypertension may offer potential benefits in mitigating the progressive risk of attrition and failure of the Fontan circulation in patients with single-ventricle physiology.
May support targeted use in select Fontan failure cases; leaves open need for prospective trials.
In recent decades, the Fontan procedure and its variations have resulted in markedly improved outcomes of patients with single-ventricle physiology. These improvements are expected to increase greatly the number of surviving patients, particularly those surviving long into adulthood. However, there is still a progressive risk of attrition and failure of the Fontan circulation over time, the underlying pathophysiology of which is not fully understood. Current evidence suggests that alterations in the structure and function of the pulmonary vasculature may play a pivotal role. Recent evidence suggests that therapies approved for pulmonary arterial hypertension may provide benefits in this increasingly important patient population.
No takes yet. Share an insight, caveat, or question.
Maurice Beghetti (2010) conducted a review in Single-ventricle physiology post-Fontan procedure. Pulmonary hypertension therapies was evaluated. Therapies approved for pulmonary arterial hypertension may provide benefits in patients with single-ventricle physiology experiencing progressive failure of the Fontan circulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: